Producción CyT
Artículo
Autoría
Fecha
2014
Editorial y Lugar de Edición
PERGAMON-ELSEVIER SCIENCE LTD
Revista
REPRODUCTIVE TOXICOLOGY (ELMSFORD, N.Y.)
(pp. 26-29)
PERGAMON-ELSEVIER SCIENCE LTD
Resumen
Información suministrada por el agente en
SIGEVA
Objective: Methotrexate (MTX) is a potent teratogen when used in high doses for cáncer or termination of tubal pregnancy. In contrast, it has been perceived as safe when used once weekly at low dose for rheumatological conditions. Methods: A prospective observational controlled study of women exposed to low dose MTX. The control group were women exposed to MTX only before conception. Results: Among the 8 MTX-exposed pregnancies, there was a case of typical MTX embryopathy, the first...
Objective: Methotrexate (MTX) is a potent teratogen when used in high doses for cáncer or termination of tubal pregnancy. In contrast, it has been perceived as safe when used once weekly at low dose for rheumatological conditions. Methods: A prospective observational controlled study of women exposed to low dose MTX. The control group were women exposed to MTX only before conception. Results: Among the 8 MTX-exposed pregnancies, there was a case of typical MTX embryopathy, the first to be described to date at this lower once weekly dose Schedule. Conclusions: This case has important implications for rheumatologists treating women of reproductive age, as the assumption of fetal safety of MTX, implied from small cohorts, is premature.
Ver más
Ver menos
Palabras Clave
METHOTREXATERHEUMATOID ARTHRITISAMINOPTERIN EMBRIOPATHYPREGNANCY